Cosmos Health Receives New Contract Manufacturing Orders Totaling 253,657 Units Across a Range of Medicines
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) announced that its subsidiary Cana Laboratories received new contract manufacturing orders from Nassington and Verisfield totaling 253,657 units.
The contracts cover multiple medicines and pharmaceutical products, supporting Cosmos Health's vertically integrated, diversified manufacturing business and reinforcing relationships with established pharmaceutical partners.
Positive
- New contract manufacturing orders totaling 253,657 units for Cana Laboratories
- Orders span a diverse range of pharmaceutical products, supporting business diversification
Negative
- None.
News Market Reaction – COSM
In the Jun 12 session, COSM gained 1.94%, reflecting a mild positive market reaction. Argus tracked a peak move of +5.5% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Crypto Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 11 | Nasdaq extension | Negative | -9.7% | Additional 180-day period granted to regain $1.00 bid compliance. |
| Jun 10 | Manufacturing agreement | Positive | +2.1% | Three-year deal for 3.9M VASCLOR GEST progesterone pessary units. |
| Jun 09 | New capsule line | Positive | -7.8% | State-of-the-art capsule line plus 5-year CERTORUN contract for 385,000 units. |
| Jun 05 | U.S. product launch | Positive | -7.4% | Launch of Oliv18 supplement, targeting large cardiovascular and antioxidant markets. |
| Jun 04 | EU distribution win | Positive | +9.8% | Pan‑EU Skroutz distribution for Sky Premium Life across all 27 EU states. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent crypto-tag news shows mixed reactions: some positive commercial updates lifted shares, while others, including compliance and manufacturing wins, saw sharp selloffs.
Over the past weeks, Cosmos Health has reported a series of growth-oriented updates under the crypto tag. These include new contract manufacturing deals such as 3.9 million VASCLOR GEST units and 385,000 CERTORUN units, plus product and distribution expansions across all 27 EU states and into U.S. nutraceutical markets. A Nasdaq bid-price extension drew a negative market response. Today’s additional 253,657-unit orders for Cana fit the pattern of scaling contract manufacturing alongside broader platform expansion.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, June 12, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that its wholly-owned subsidiary, Cana Laboratories ("Cana"), has received new contract manufacturing orders from Nassington and Verisfield for a combined 253,657 units across a range of medicines and other pharmaceutical products.
Under the orders, Cana will manufacture Gritse oral solution 0.4 mg/ml (bottle x 150 ml); Gritse forte oral solution 2 mg/ml (bottle x 50 ml); Gritse forte oral solution 4 mg/ml (bottle x 50 ml); Fungofort cutaneous spray, solution (30 ml); Paco-4 tablets (250+250+65+35 mg); dexamethasone 2 mg/5 ml, in 50 ml and 150 ml bottle and oral solution presentations; and Foproct rectal cream (1 +
Greg Siokas, CEO of Cosmos Health, stated: "These orders reflect the demand for Cana's contract manufacturing capabilities and the strength of our vertically integrated platform. By deepening our relationships with established pharmaceutical partners across a broad range of products, we continue to build a diversified manufacturing business that supports long-term value creation for our shareholders.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
